BioLineRx Releases Q2 2026 Financial Results - Alphastreet

BioLineRx (BLRX) reported Q2 2026 earnings with $0.00 EPS, matching estimates. Revenue was $294,000, down from $304,000 in Q2 2025. The company had a net loss of $4.3M and $13.1M in cash and equivalents. BioLineRx is focused on oncology and rare disease treatments.

Original reporting
Published Aug 31, 2026, 2:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 31, 2026, 7:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$BLRX
Neutral
medium confidence
Mentioned
$BLRX
Relevance
5/10
AlphAI data visualization · based on news.alphastreet.com
Decision brief

The 30-second read

$BLRXNeutralLow
01

Why it matters

The earnings numbers are modest and expected, offering little new trading edge.

02

Market read

Earnings are a routine disclosure for a micro‑cap biotech with limited immediate trading relevance.

03

What to watch

Potential upcoming clinical trial readouts not mentioned in the release.

Relevance 5/10Novelty 5/10Timing: post‑market earnings release

Background

BioLineRx is an Israeli biotech developing oncology and rare‑disease therapeutics.

Company-level read

Ticker impact

$BLRXNeutralMedium confidence
Context

Q2 2026 earnings release showing $294k revenue and $4.3M net loss.

Expected impact

minor downside pressure or flat movement

Evidence & confidence

Revenue decline and loss are in line with expectations for a development‑stage biotech; no new catalyst.

Market effects

Reflects ongoing funding pressures in the oncology biotech sector.

Limited to Israeli‑based biotech investors.

Minimal; no broader market effect.

Counterpoint

If cash runway extends, the stock could be undervalued despite the loss.

Key entities

  • BioLineRx Ltd.

    NASDAQ‑listed biotech reporting Q2 2026 results.

Related articles

$BLRXLow

BioLineRx initiates fourth cohort in GLIX1 brain tumor trial

BioLineRx and Hemispherian started the fourth cohort of a Phase 1/2a trial for GLIX1, a treatment for high-grade glioma. The study showed no significant adverse events. Preclinical data indicated tumor eradication and growth inhibition. BioLineRx expects results in early 2027. According to the companies, GLIX1 demonstrated brain penetration and biological activity.

$BLRXMedAI 8/10

BioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026

BioLineRx (BLRX) and Hemispherian presented Phase 1/2a clinical study and pre-clinical updates for GLIX1 at the SNO 2026 Annual Meeting. The study, ongoing with no safety concerns, includes a fourth cohort and plans for window-of-opportunity cohorts. GLIX1 showed robust, dose-dependent antitumor activity in multiple glioblastoma models, including brain penetration and dose-dependent increases in tumor 5hmC.

$BLRXMedAI 8/10

BioLineRx, Hemispherian report GLIX1 data at ESMO 2026

BioLineRx (BLRX) and Hemispherian presented preclinical data at ESMO 2026, showing GLIX1's synergy with PARP inhibitors in HR-proficient ovarian cancer models. The combination demonstrated significant tumor growth inhibition. GLIX1 is in a Phase 1/2a trial for glioblastoma, with plans to add an ovarian cancer arm. According to the companies, the data suggest GLIX1 could expand PARP inhibitors' activity to HR-proficient tumors.

$BLRXLowAI 8/10

BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026

BioLineRx and Hemispherian presented preclinical data at ESMO 2026 showing GLIX1's synergy with PARP inhibitors in HR-proficient ovarian cancer. GLIX1, a TET2 activator, demonstrated tumor growth inhibition in combination with olaparib, veliparib, and niraparib. BioLineRx plans to add an ovarian cancer arm to its ongoing Phase 1/2a trial for glioblastoma.

$BLRXMedAI 8/10

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)

BioLineRx (BLRX) and Hemispherian AS announced preclinical data and trial design for GLIX1, a TET2 activator, will be presented at EANO 2026. GLIX1 showed anti-tumor activity in glioblastoma models, with a Phase 1/2a trial actively enrolling patients. BioLineRx is developing GLIX1 for glioblastoma and other solid tumors.